Tuesday - September 15, 2026
AstraZeneca: Enhertu Demonstrated a Median Progression-free Survival of 14.3 Months as 1st-line Therapy in Patients With HER2-mutant Advanced Non-small Cell Lung Cancer in DESTINY-Lung04 Phase III Trial
September 15, 2026
WILMINGTON, Delaware, Sept. 15 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapy

AstraZeneca . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products